OLEMA PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Basic Shares Outstanding (Weighted Average) of 104.45 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 104.45M shares, a 22.17% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 102.80M shares, a 20.34% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 91.36M shares, a 21.19% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 85.73M shares, a 49.72% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 87.01M shares, a 48.11% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 58.74M shares, a 29.83% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 45.25M shares, a 13.13% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 40.00M shares, a 1.19% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 104.45M shares 10-Q · filed 2026-08-10 | 103.63M shares 10-Q · filed 2026-08-10 | 99.54M shares derived: average of 3 quarters · filed 2026-08-10 | 96.09M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 102.80M shares 10-Q · filed 2026-05-12 | 97.08M shares derived: average of 2 quarters · filed 2026-05-12 | 93.30M shares derived: average of 3 quarters · filed 2026-05-12 | 91.35M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | 91.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 88.55M shares derived: average of 2 quarters · filed 2026-03-16 | 87.53M shares derived: average of 3 quarters · filed 2026-08-10 | 87.01M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 85.73M shares 10-Q · filed 2025-11-10 | 85.61M shares derived: average of 2 quarters · filed 2026-08-10 | 85.55M shares 10-Q · filed 2025-11-10 | 83.01M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 85.50M shares 10-Q · filed 2026-08-10 | 85.46M shares 10-Q · filed 2026-08-10 | 82.11M shares derived: average of 3 quarters · filed 2026-08-10 | 75.89M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 85.43M shares 10-Q · filed 2026-05-12 | 80.41M shares derived: average of 2 quarters · filed 2026-05-12 | 72.69M shares derived: average of 3 quarters · filed 2026-05-12 | 68.59M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 75.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 66.33M shares derived: average of 2 quarters · filed 2026-03-16 | 62.98M shares derived: average of 3 quarters · filed 2026-03-16 | 58.74M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 57.26M shares 10-Q · filed 2025-11-10 | 56.77M shares derived: average of 2 quarters · filed 2025-11-10 | 53.19M shares 10-Q · filed 2025-11-10 | 56.03M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 56.28M shares 10-Q · filed 2025-08-11 | 55.93M shares 10-Q · filed 2025-08-11 | 55.62M shares derived: average of 3 quarters · filed 2025-08-11 | 52.96M shares derived: average of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | 55.57M shares 10-Q · filed 2025-05-13 | 55.28M shares derived: average of 2 quarters · filed 2025-05-13 | 51.85M shares derived: average of 3 quarters · filed 2025-05-13 | 49.07M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 54.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 49.98M shares derived: average of 2 quarters · filed 2025-03-18 | 46.90M shares derived: average of 3 quarters · filed 2025-03-18 | 45.25M shares 10-K · filed 2025-03-18 |
| 2023-09-30 | 44.98M shares 10-Q · filed 2024-11-12 | 42.85M shares derived: average of 2 quarters · filed 2024-11-12 | 42.00M shares 10-Q · filed 2024-11-12 | 41.56M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 40.72M shares 10-Q · filed 2024-08-06 | 40.47M shares 10-Q · filed 2024-08-06 | 40.42M shares derived: average of 3 quarters · filed 2024-08-06 | 40.33M shares derived: average of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | 40.35M shares 10-Q · filed 2024-05-08 | 40.27M shares derived: average of 2 quarters · filed 2024-05-08 | 40.19M shares derived: average of 3 quarters · filed 2024-05-08 | 40.12M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 40.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 40.11M shares derived: average of 2 quarters · filed 2024-03-11 | 40.05M shares derived: average of 3 quarters · filed 2024-03-11 | 40.00M shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 40.04M shares 10-Q · filed 2023-11-07 | 39.98M shares derived: average of 2 quarters · filed 2023-11-07 | 39.93M shares 10-Q · filed 2023-11-07 | 39.88M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 39.92M shares 10-Q · filed 2023-08-08 | 39.88M shares 10-Q · filed 2023-08-08 | 39.83M shares derived: average of 3 quarters · filed 2023-08-08 | 39.78M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 39.83M shares 10-Q · filed 2023-05-09 | 39.79M shares derived: average of 2 quarters · filed 2023-05-09 | 39.73M shares derived: average of 3 quarters · filed 2023-05-09 | 39.65M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 39.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 39.68M shares derived: average of 2 quarters · filed 2023-03-09 | 39.59M shares derived: average of 3 quarters · filed 2023-03-09 | 39.52M shares 10-K · filed 2023-03-09 |
| 2021-09-30 | 39.61M shares 10-Q · filed 2022-11-08 | 39.51M shares derived: average of 2 quarters · filed 2022-11-08 | 39.45M shares 10-Q · filed 2022-11-08 | 34.65M shares derived: average of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | 39.42M shares 10-Q · filed 2022-08-09 | 39.37M shares 10-Q · filed 2022-08-09 | 32.99M shares derived: average of 3 quarters · filed 2022-08-09 | 25.40M shares derived: average of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | 39.33M shares 10-Q · filed 2022-05-09 | 29.78M shares derived: average of 2 quarters · filed 2022-05-09 | 20.73M shares derived: average of 3 quarters · filed 2022-05-09 | 16.19M shares derived: average of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | 20.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 11.43M shares derived: average of 2 quarters · filed 2022-02-28 | 8.48M shares derived: average of 3 quarters · filed 2022-02-28 | 7.02M shares 10-K · filed 2022-02-28 |
| 2020-09-30 | 2.62M shares 10-Q · filed 2021-11-10 | 2.61M shares derived: average of 2 quarters · filed 2021-11-10 | 2.62M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 2.59M shares 10-Q · filed 2021-08-10 | 2.59M shares 10-Q · filed 2021-08-10 | ||
| 2019-12-31 | 2.59M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |